PLATINUM EQUITY ACQUIRES ASP GLOBAL
Financial terms were not disclosed.
Based in
ASP's portfolio spans a diverse range of consumable product categories, including lab supplies, blood collection, wound and injury protection, critical care, staff apparel and rehab mobility.
"Healthcare providers are intensely focused on managing costs and increasing control of their supply chains," said Platinum Equity Co-President
Platinum Equity Managing Director
"ASP has an experienced management team that has articulated a compelling vision for the future," said Price. "We have a shared belief in what ASP can become and are excited to get to work."
ASP Global President and CEO
"We are proud of the business ASP has built and have ambitious long-term plans to continue growing," said Shaver. "Platinum's expanded access to capital, M&A resources and operational expertise can help us achieve our goals and create new opportunities for ASP to serve the evolving needs of our customers."
"ASP has a lot of runway to continue expanding organically and we expect to be active in pursuit of additional M&A opportunities, too," added Price.
Platinum Equity currently owns healthcare products distributor NDC, which serves a different part of the medical supplies market. ASP and NDC will operate as separate, standalone companies in Platinum Equity's portfolio.
Solomon Partners served as financial advisor to Platinum Equity on the ASP acquisition. Latham and Watkins served as legal counsel to Platinum Equity on the transaction.
About Platinum Equity
Founded in 1995 by
About ASP Global
With headquarters in the
Contact:
Platinum Equity
[email protected]
View original content:https://www.prnewswire.com/news-releases/platinum-equity-acquires-asp-global-302215015.html
SOURCE Platinum Equity
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Signia Introduces MaX, Powered by Acoustic Intelligence™: World's First AI Hearing Aid Platform with 4 DNNs
- American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
- GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share